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Erythrocytosis is a common reason for referral to hematology,
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morbidity and mortality if untreated.1 Recent changes to the World

4

Health Organization (WHO) definition of PV reduced the hemoglobin
Correspondence

thresholds required for diagnosis, leading to overlap with the normal
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ary erythrocytosis often requires laboratory investigation, including
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serum erythropoietin (EPO) measurement and/or molecular testing
for JAK2 mutations. Although JAK2 mutations are found in other
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presence of JAK2 mutations is highly sensitive and specific for PV.3
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Various approaches to the investigation of erythrocytosis are
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found in the literature: some start with EPO measurement,4 while
others advocate concurrent EPO and JAK2 testing.5 In a recent issue
of this journal, Tefferi and Barbui3 recommend upfront JAK2 mutation
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screening in patients with suspected PV. The sequential approach

1. Terpos E, Trougakos IP, Apostolakou F, et al. Age-dependent and
gender-dependent antibody responses against SARS-CoV-2 in health
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mRNA vaccine. Am J Hematol. 2021;96(7):E257–E259.
2. Rosati M, Terpos E, Agarwal M, et al. Distinct neutralization profile of
spike variants by antibodies induced upon SARS-CoV-2 infection or
vaccination. Am J Hematol. 2022;97(1):E3–E7.
3. Bergamaschi C, Terpos E, Rosati M, et al. Systemic IL-15, IFN-γ, and
IP-10/CXCL10 signature associated with effective immune response
to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep.
2021;36(6):109504.

starting with EPO measurement is premised on a normal or high EPO
level having a high negative predictive value (NPV) to rule out PV. In
contrast, the justification for concurrent or upfront JAK2 testing is
one of clinical expediency in patients with a high pretest probability
for PV.
Most evidence for EPO's utility in the investigation of
erythrocytosis predates the advent of molecular testing for PV,6 and
the added value of EPO measurement beyond JAK2 testing has been
brought into question by more recent studies.7 This descriptive study
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revisited the utility of EPO measurement in the era of JAK2 testing by

(84%) being arterial events. Of the JAK2-negative patients with

examining serum EPO distribution in a large real-world cohort of

subnormal EPO levels (n = 15), potential confounding factors

patients with erythrocytosis referred to our center, an academic

included acute kidney injury (n = 4), chronic kidney disease (n = 2),

healthcare organization, which serves a population of approximately

and liver disease (n = 5); none was identified as having EPO receptor

2 million in Ontario, Canada.

mutations.

We reviewed all patients aged 18 years or older investigated for

ROC analysis established 4.75 mIU/mL as the optimal cut point;

erythrocytosis (>160 g/L for women or >165 g/L for men) with JAK2

EPO levels below this threshold had a sensitivity of 90.3% and speci-

mutation testing between January 1, 2015, and May 12, 2021,

ficity of 88.0% for predicting a diagnosis of PV (area under the curve

extracting data on JAK2 mutation analysis, serum EPO levels, final

[AUC] = 0.94, Figure 1B). For use as an initial screening test to

diagnosis, and risk factors for secondary erythrocytosis. All patients

exclude JAK2-positive PV, a higher sensitivity (95.8%) could be

with available EPO levels were included. JAK2 testing was performed

achieved by increasing the EPO threshold to 7.15 mIU/mL. An EPO

by either quantitative polymerase chain reaction (qPCR) using the

level > 27 mIU/mL was required to achieve a sensitivity of 100% and

Roche 480 LightCycler (La Roche AG, Switzerland), single nucleotide

a NPV of 100% to effectively rule out JAK2-positive PV. Applied to

polymorphism (SNP) allelotyping using the Agena MassARRAY system

our cohort, only 4.3% (n = 30) were at or above this threshold, mean-

(Agena Biosciences, USA), or next generation sequencing (NGS) panel

ing that an EPO level could have been used to rule out

using the Oncomine Myeloid Research Assay (ThermoFisher Scien-

JAK2-positive PV.

tific, USA). qPCR and SNP allelotyping assays tested for JAK2V617F

Given the significant number of PV patients with normal EPO

mutations; the NGS panel screened for any JAK2 mutations in exons

levels (≥2.6 mIU/mL), we reviewed secondary causes that might

12–15, in addition to sequence variants in 40 other genes (including

potentially explain “inappropriately normal” EPO levels in these

SH2B3) and 29 fusion driver genes associated with myeloid malignan-

patients. We found that risk factors for secondary erythrocytosis were

cies. Serum EPO levels were measured by chemiluminescent immuno-

overrepresented in PV patients with normal/high vs. low EPO levels,

assay (Unicel DXi 800; Beckman Coulter, USA) with a normal range of

including smoking (40.0% vs. 14.9%) and obstructive sleep apnea

2.6–18.5 mIU/mL. We performed receiver operating characteristic

(16.0% vs. 4.3%), but only smoking reached statistical signifi-

(ROC) analysis to evaluate the diagnostic accuracies of different EPO

cance (p = .022).

levels in predicting JAK2-positive PV. Given the high morbidity and

In summary, these data on serum EPO distribution in a large

mortality of untreated PV, we used a high NPV (>99%) to determine

real-world cohort of patients referred for suspected PV suggest that

the threshold EPO level needed to exclude a diagnosis of PV.

EPO measurement may have limited added value when used concur-

Over the 5-year study period, a total of 883 patients referred for

rently with JAK2 testing to rule out PV. We demonstrated that nor-

erythrocytosis underwent molecular testing. Of these patients,

mal EPO levels are present in over a third of patients with JAK2-

696 (78.8%) had EPO levels measured; most were ordered simulta-

positive PV and therefore do not distinguish between PV and sec-

neously with JAK2 testing. Patient characteristics are shown in

ondary erythrocytosis. A higher EPO threshold (>7.15 mIU/mL)

Table S1, stratified by JAK2 mutation status. The final diagnosis was

showed improved sensitivity (95.8%), suggesting that EPO testing

PV in all 72 patients with JAK2 mutations (10.3%), and the remaining

may still play an initial role if JAK2 testing is not available. Nonethe-

624 patients (89.7%) were diagnosed with secondary causes of

less, in our cohort, a very high EPO threshold (>27 mIU/mL) was

erythrocytosis, most commonly smoking (42.5%), obstructive sleep

required to rule out PV with sufficient confidence to avoid JAK2

apnea (32.7%), chronic obstructive pulmonary disease (14.6%), and

testing, a level that would have excluded PV in only a small propor-

testosterone use (10.3%). Distribution of risk factors for secondary

tion of patients (4.3%).

erythrocytosis is shown in Table S2. The median EPO levels for JAK2-

These data question the value of simultaneous EPO and JAK2

positive and JAK2-negative patients were 1.8 mIU/mL (range 0–26.4

testing in the diagnosis of PV. EPO may retain diagnostic utility in

mIU/mL) and 9.2 mIU/mL (range 1.3–762 mIU/mL), respectively

sequential testing; however, our findings challenge the premise

(p < .001). There was a considerable overlap in EPO levels between

implicit in many sequential algorithms that normal or high EPO levels

JAK2-positive and -negative patients, with 80.2% (n = 559) of our

are sufficient to exclude PV. Implementation of a diagnostic algo-

cohort falling within the normal range (Figure 1A). Of the

rithm and selection of EPO thresholds must be based on local dis-

JAK2-positive patients, 25 (34.7%) had EPO levels at or above the

ease prevalence and test performance rather than normal reference

lower limit of normal (≥2.6 mIU/mL). One JAK2-positive patient had

ranges for EPO, which vary depending on population characteristics

an EPO level above 18.5 mIU/mL, which may have been explained

and laboratory methods, and are difficult to extrapolate between set-

by concomitant heavy smoking. EPO testing was performed at the

tings. The diagnostic utility of EPO is further confounded by

time of initial consultation in all patients; no patients were identified

preanalytical variables, which include diurnal variation, as well as risk

as being on active treatment for erythrocytosis, either in the form of

factors for hypoxia such as smoking, obstructive sleep apnea, and

phlebotomy or cytoreductive therapy, at the time of measurement.

place of residence. In our cohort, smoking was overrepresented in

Of the JAK2-positive patients, 34.7% (n = 25) had a prior history of

PV patients with normal or high EPO levels, in keeping with previous

thrombosis at the time of initial presentation, with the majority

findings.7
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F I G U R E 1 (A) Distribution of erythropoietin (EPO) levels JAK2-positive (n = 72) and negative patients (n = 624); (B) Receiver operating
characteristic (ROC) curve for EPO as a predictor of JAK2-positive polycythemia vera (PV). Shaded area indicates 95% confidence intervals. Points
indicate different EPO thresholds: = 2.6 mIU/mL (lower limit of normal), sensitivity 67%, specificity 97%; = 4.75 mIU/mL (optimal cut point),
sensitivity 90%, specificity 88%; = 7.15 mIU/mL (threshold with sensitivity > 95%), sensitivity 96%, specificity 67%; = 18.5 mIU/mL (upper
limit of normal), sensitivity 99%, specificity 12%; = 27 mIU/mL (threshold with NPV >99%), sensitivity 100%, specificity 5%

Limitations include our study's retrospective design, making us
unable to control for variables such as variation in timing of EPO mea-

rarely reach a threshold sufficient to exclude a diagnosis of PV with a
high NPV.

surement and method of JAK2 testing. Our study was conducted at a

While EPO measurement is generally less costly than molecular

tertiary referral center with ready access to molecular diagnostics:

diagnostics, the common practice of simultaneously ordering EPO

it does not address the utility of EPO measurement in low

levels and JAK2 mutation analysis negates any potential cost sav-

resource settings or at centers with limited access to JAK2 testing.

ings. In patients with a high pretest probability of PV, however,

In such settings, EPO testing may be helpful provided that the user

the sequential approach is likely not a cost-effective strategy for

is aware of the performance characteristics of the assay in their

investigating erythrocytosis and may only add to costs in the form

patient population. Although our cohort is more representative of

of unnecessary testing, repeat clinic visits and diagnostic delays,

all

for

justifying the approach of upfront JAK2 mutation screening

erythrocytosis compared to previous studies examining the utility

recently proposed by Tefferi and Barbui.3 With declining costs of

patients

referred

to

specialty

hematology

clinics

6

of EPO testing, the prevalence of PV in our study remains higher

molecular diagnostics, an updated cost–benefit analysis is needed

than in population-based cohorts; in lower prevalence settings, ini-

to better define the role of EPO testing in the work up of

tial

excluding

PV. Given rising referrals for suspected PV in the wake of the

PV. Additionally, EPO measurement plays a diagnostic role in the

2016 WHO revision, further research should also examine whether

rare subgroup of PV patients without JAK2V617F or exon 12 muta-

alternate clinical or laboratory data aside from EPO levels, such as

tions.3 Given our objective to address the practical utility of EPO

lactate dehydrogenase levels or complete blood count parameters,8

measurement in patients referred for erythrocytosis, we used ele-

might be used to more effectively triage JAK2 testing in patients

vated hemoglobin levels as an inclusion criteria for our study; we

with erythrocytosis.

EPO

testing

may

have

greater

utility

in

acknowledge this is an imperfect surrogate for red cell mass, which
is no longer routinely measured in practice.
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their disease. In particular, the treatment of patients who are tripleclass refractory (TCR, i.e., refractory to an immunomodulatory agent, a
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cant challenge with a median overall survival of 9 months and limited
therapeutic options available.1,2 In 2021, the US Food and Drug
Administration approved Idecabtagene vicleucel, the first chimeric
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antigen receptor-T-cell (CAR-T) therapy, for patients with relapsed/
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refractory multiple myeloma (RRMM) who have received at least four
prior lines of therapy. Approval was based on the single arm phase II
KARMMA study among 128 patients with heavily pretreated MM
(84% TCR) demonstrating an overall response rate of 73%, complete
response rate of 33%, and a median progression-free survival of
8.8 months; efficacy parameters considered transformative in this
setting.3
While the FDA approval of CAR-T therapy among patients with
RRMM represents a significant addition to the therapeutic arsenal, its
immediate benefit in real-world patients with MM, particularly older
adults, is unknown. Published real-world evidence suggests that 32–
61% and 14–38% of patients with symptomatic MM receive secondand

third-line

therapy,

respectively.4

Furthermore,

the

very

reeligibility criteria used by the phase II KarMMa study may further
limit the number of patients who are considered for this therapy.
We used the Flatiron Health Electronic Health Record (EHR)derived deidentified database, a longitudinal database comprising
patient-level

structured

and

unstructured

data,

curated

via

technology-enabled abstraction, originating from approximately
280 cancer clinics across the United States (≈800 sites of care). Our

